Biotechnology IPOs are taking the lead in the US primary market over AI-linked listings, with a steady stream of summer debuts expected as bankers line up transactions. The article highlights “standout returns” from the biotech sector, indicating stronger investor appetite for these new offerings rather than AI-related IPOs.
Biotechnology IPOs are taking the lead in the US primary market over AI-linked listings, with a steady stream of summer debuts expected as bankers line up transactions. The article highlights “standout returns” from the biotech sector, indicating stronger investor appetite for these new offerings rather than AI-related IPOs.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.35
